Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Schibsted Tillväxtmedier in connection with its divestment of Prisjakt
Mandate

Vinge advises Schibsted Tillväxtmedier in connection with its divestment of Prisjakt

May 06, 2025 M&A Employment and Benefits Data protection and processing of personal data Intellectual Property Commercial Agreements

Schibsted Tillväxtmedier has entered into an agreement for the sale of Prisjakt to eEquity. The consideration is expected to amount to around SEK 500 million. Schibsted has owned Prisjakt for approximately 20 years and the divestment is made as part of Schibsted’s ongoing streamlining of its organisation and portfolio.

The transaction is expected to close in June 2025 and is conditional upon approval from the Swedish Competition Authority.

Vinge’s team consisted mainly of Johan Larsson, Johan Winnerblad and Gustav Wahlberg (M&A), Nicklas Thorgerzon (GDPR), Eva Fredrikson, Christoffer Nordin, Siri Blomberg and Carl Lexenberg (Kommersiella avtal), Alice Göransson (Commercial agreements) as well as Johan Gavelin (IP).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025